Breaking News Headlines Today | Ground News

See every side of every news story

lifesciencesbc.ca image

News from lifesciencesbc.ca

Ground News rates lifesciencesbc.ca’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

lifesciencesbc.ca’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about lifesciencesbc.ca

Where is lifesciencesbc.ca located?lifesciencesbc.ca's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top lifesciencesbc.ca News

First clinical trial of pig kidney transplants gets underway — An inquisitive young pig explores the farm, surrounded by greenery and open space, showcasing rural life. by mali maeder/Pexels / Pexels

Science · United States

First clinical trial of pig kidney transplants gets underway

65% Center coverage: 37 sources

The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives. United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully at NYU Langone Health.See the Story

Vertex (NASDAQ: VRTX): Povetacicept Cuts Proteinuria 64% in IgAN, 82% in pMN

Boston, Massachusetts · Boston

Vertex (NASDAQ: VRTX): Povetacicept Cuts Proteinuria 64% in IgAN, 82% in pMN

Coverage: 2 sources

48-week RUBY-3 shows eGFR stabilization, 90% hematuria resolution and 53% remission in IgAN; 40% complete remission in pMN. BLA rolling submission planned.See the Story

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

100% Center coverage: 2 sources

FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a…See the Story

Breaking News Topics Related to lifesciencesbc.ca